Evaluation of HPV DNA HR assay in females as a marker of recurrent disease following treatment of cervical intraepithelial neoplasia.
Abstract
AIM
The basic assumption of the prevention of cervical cancer is to early detect and treat CIN (cervical intraepithelial neoplasia)
as well as to prevent recurrence of neoplasia after therapy This study involved comparison of the cytology test value and
determination of HPV (human papilloma virus) DNA in women treated for CIN so as to find a sensitive and specific marker of
disease recurrence.
METHODS
A group of 107 females after CIN treatment underwent 14-month follow-up and regular cytological and molecular evaluations.
RESULTS
Based on the follow-up data the recurrence of CIN was found in 9 females who despite effective therapy for the entire follow-up
period were HPV positive. Evaluation of value of HR (high risk)--HPV DNA assay used to detect CIN showed its 100% sensitivity
CONCLUSION
The HR-HPV DNA assay is likely to be a valuable diagnostic tool facilitating more precise detection of recurrent neoplasia
risk than cytological test alone.
Authors
Mikolajczyk K, Kedzia W, Zaba R, Silny W
Institution
Chair and Department of Dermatology of the University of Medical Sciences in Poznan, Poland. katarzyna.mikolajczyk@op.pl
Source
Ginekologia polska 82:9 2011 Sep pg 670-4MeSH
AdultCervical Intraepithelial Neoplasia
Cervix Uteri
DNA, Viral
Female
Follow-Up Studies
Humans
Middle Aged
Neoplasm Recurrence, Local
Papillomaviridae
Papillomavirus Infections
Poland
Risk Factors
Uterine Cervical Neoplasms
Vaginal Smears
Women's Health
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22379926
Log In

